← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-6 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
CGTBiologicstaleFrontera TherapeuticsPhase 2

FT-003 (FT-003)

Diabetic Macular Edema · Neovascular Age-related Macular Degenera

#NeovascularAge-relatedMacularDeg#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 4상태 RECRUITING
AntibodystaleEisai Inc.Phase 2

Farletuzumab ecteribulin (Farletuzumab ecteribulin)

Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Phase2#항체#면역항체+2
효능 ORR 20%임상시험 4상태 RECRUITING
CGTBiologicstalePolina StepenskyPhase 2

HBI0101 CART (HBI0101 CART)

Multiple Myeloma, Refractory to Standard Treatment; Multiple Myeloma, Relapsed · Systemic Sclerosis (SSc)

#SystemicSclerosisSSc#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 4상태 RECRUITING
ADCBiologicstaleFBD Biologics LimitedPhase 2

HCB101 (HCB101)

Solid Cancer · Solid Cancer

#SolidCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
ADCBiologicstaleAbbViePhase 2

IMGN632 (IMGN632)

Blastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm · Blastic Plasmacytoid Dendritic Cell Neop

#BlasticPlasmacytoidDendriticCell#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
AntibodystaleEli Lilly and CompanyPhase 2

Icrucumab (Icrucumab)

Colon Cancer; Rectal Cancer · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#항체#면역항체+4
효능 ORR 28.8%임상시험 4상태 ACTIVE
CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

KRAS TCR-Transduced PBL (KRAS TCR-Transduced PBL)

Metastatic Solid Cancers; Colorectal Cancer · Gastrointestinal Carcinoma

#GastrointestinalCarcinoma#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 4상태 RECRUITING
ADCBiologicstaleMerck Healthcare KGaA, Darmstad…Phase 1

M9140 (M9140)

Solid Tumors; Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
AntibodystaleAstraZenecaPhase 3

MEDI4736+Tremelimumab (MEDI4736+Tremelimumab)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase3#항체#면역항체+2
효능 ORR 37.4%임상시험 4상태 ACTIVE
ADCBiologicstaleMinghui Pharmaceutical (Hangzho…Phase 2

MHB036C (MHB036C)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

MK-3120 (MK-3120)

Bladder Cancer · Bladder Cancer

#BladderCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
ADCBiologicstaleMillennium Pharmaceuticals, Inc.Phase 1

MLN0264 (MLN0264)

Advanced Gastrointestinal Malignancies · Advanced Gastrointestinal Malignancies

#AdvancedGastrointestinalMalignan#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 0%임상시험 4상태 ACTIVE
ADCBiologicstaleBristol-Myers SquibbPhase 2

MORAb-202 (MORAb-202)

Carcinoma, Non-Small-Cell Lung · Neoplasms, Ovarian

#NeoplasmsOvarian#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 20%임상시험 4상태 DISCONTINUED
ADCBiologicstaleNektar TherapeuticsPhase 2

NKTR-255 (NKTR-255)

Multiple Myeloma; Non-Hodgkin Lymphoma · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 RECRUITING
AntibodystaleBiogenPhase 2

Natalizumab (Natalizumab)

Crohn's Disease · Multiple Sclerosis, Relapsing-Remitting

#MultipleSclerosisRelapsing-Remit#Antibody#Phase2#항체#면역항체+3
효능 ORR 52%임상시험 4상태 ACTIVE
ADCBiologicstaleRochePhase 2

trastuzumab (Herceptin, Patritumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 RECRUITING
AntibodystaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 95%임상시험 4상태 ACTIVE
ADCBiologicstaleSanofiPhase 2

SAR439459 (SAR439459)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, SD-101 + Pembrolizumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 3.2%임상시험 4상태 RECRUITING
ADCBiologicstaleSeagen Inc.Phase 1

SGN-CD19A (SGN-CD19A)

Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 ACTIVE

53 / 177 페이지

← 이전다음 →